Arbor Pharmaceuticals Announces Closing of Series A Financing and Initial Deployment of the Company’s Pediatric Sales Force

January 7, 2009

RALEIGH, N.C., Jan. 7 /PRNewswire/ — Arbor Pharmaceuticals (“Arbor”), an
emerging specialty pharmaceutical company focused exclusively on pediatric
medicine, announced today that the company recently closed its Series A
financing. This latest round of investment capital will support the launch of
Arbor’s third product and facilitate continued growth of the company and its
current and pipeline products. The Series A funding was participated in by
several new investors in addition to the company’s original investment group.
Since the founding of Arbor in 2006 the company has launched two novel
prescription products for ear infections (ZINOTIC(R) and NEOTIC(R)) and is
developing a pipeline of unique nonantibiotic products for common pediatric

“This new round of funding will allow the company to continue on its
significant growth trajectory by introducing new and important treatment
options for children. We are grateful to the company’s investors for
recognizing the significant value that Arbor has created as an emerging leader
in pediatric pharmaceuticals. Arbor is well positioned to continue to
introduce important and novel pediatric treatment options and further
establish Arbor as a leader in the growing pediatric pharmaceuticals market,”
says Jarrett Disbrow, President & CEO of Arbor.

In addition to completing the Series A financing Arbor has recently
deployed a specialty sales force focused on promoting the company’s products
to pediatricians across the United States. The company also has a promotional
agreement with a partner company to promote Arbor’s products in several
markets. Arbor’s products are now being promoted in more than 25 major U.S.
metropolitan areas. The company plans to expand its sales force in the coming

About Arbor Pharmaceuticals

Arbor Pharmaceuticals is a Raleigh, North Carolina-based specialty
pharmaceutical company focused exclusively on the growing pediatric market.
Arbor actively licenses, develops and commercializes pediatric products
initially focused on nonantibiotic products for the treatment of various ear
infections and currently markets two patented products, ZINOTIC(R) and
NEOTIC(R). The company intends to become the leading pediatric pharmaceutical
company by developing and commercializing a robust pipeline of late-stage
products for common pediatric conditions. Arbor will launch a novel treatment
option for recurrent middle ear infections in early 2009.

To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com or
send email inquiries to info@arborpharma.com.

SOURCE Arbor Pharmaceuticals

Source: newswire

comments powered by Disqus